---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-009748"
form_type: "8-K"
ticker: "AVR"
cik: "0002011514"
company_name: "Anteris Technologies Global Corp."
filed_at: "2025-03-21T23:59:59+00:00"
generated_at: "2026-05-24T09:20:54.909869+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Anteris DurAVR THV reports zero PPM at one year in small annuli patients

## Summary
- One-year hemodynamic data: EOA 2.1±0.2 cm², mean gradient 8.6±2.6 mmHg, DVI 0.58 (n=65).
- Zero prosthesis-patient mismatch (PPM) in small annuli patients; commercial valves report 11-35% PPM.
- No valve or cardiovascular related mortality at one year; consistent safety profile.
- Data to support planned IDE submission to FDA for DurAVR THV pivotal study.
- Results presented at Sydney Valves late-breaking clinical trial session on March 21, 2025.

## SEC filing metadata
- accession: 0001140361-25-009748
- form_type: 8-K
- ticker: AVR
- cik: 0002011514
- company_name: Anteris Technologies Global Corp.
- filed_at: 2025-03-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2011514/000114036125009748/0001140361-25-009748-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2011514/000114036125009748/ef20045825_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-009748
- JSON: https://secwatch.observer/filing/0001140361-25-009748.json
- Plain text: https://secwatch.observer/filing/0001140361-25-009748.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.